Control of the of the final stage of immune-mediated diabetes by ISO-1, an antagonist of macrophage migration inhibitory factor | Zendy

Ivana Stojanović | Zendy; Danijelа Maksimović-Ivanić | Zendy; Yousef AlAbed | Zendy; Ferdinando Nicoletti | Zendy; Stanislava StošićGrujičić | Zendy

Open Access

Control of the of the final stage of immune-mediated diabetes by ISO-1, an antagonist of macrophage migration inhibitory factor

Author(s) -

Ivana Stojanović,

Danijelа Maksimović-Ivanić,

Yousef AlAbed,

Ferdinando Nicoletti,

Stanislava StošićGrujičić

Publication year - 2008

Publication title -

archives of biological sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 25

eISSN - 1821-4339

pISSN - 0354-4664

DOI - 10.2298/abs0803389s

Subject(s) - macrophage migration inhibitory factor , cytokine , pancreatic islets , in vivo , immune system , islet , pancreas , diabetes mellitus , immunology , inflammation , in vitro , macrophage , biology , cancer research , microbiology and biotechnology , pharmacology , endocrinology , biochemistry

We recently showed that attenuation of inflammatory cytokine MIF with pharmacological inhibitor ISO-1 down-regulates the immune-mediated diabetes in mice. Here we explore the effects of MIF neutralization by ISO-1 on the local inflammatory pathway of the disease. In vivo treatment of mice with ISO-1 inhibited the expression of pro-inflammatory cytokines and iNOS in the pancreatic islets. Moreover, ISO-1 affected in vitro cytokine-induced NO production by fibroblasts, endothelial cells, insulinoma cells, and pancreatic islets, and rescued β cells from NO-dependent damage. These results suggest regulatory potential of ISO-1 at the level of the pancreas which can preserve the target tissue from autoimmune attack

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research